Insulin-like growth factor-I in growth and metabolism
Research output: Contribution to journal › Journal article › Research
Standard
Insulin-like growth factor-I in growth and metabolism. / Backeljauw, P; Bang, P; Dunger, D B; Juul, A; Le Bouc, Y; Rosenfeld, R.
In: Journal of Pediatric Endocrinology and Metabolism, Vol. 23, No. 1-2, 2010, p. 3-16.Research output: Contribution to journal › Journal article › Research
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Insulin-like growth factor-I in growth and metabolism
AU - Backeljauw, P
AU - Bang, P
AU - Dunger, D B
AU - Juul, A
AU - Le Bouc, Y
AU - Rosenfeld, R
PY - 2010
Y1 - 2010
N2 - Deficiency of insulin-like growth factor-I (IGF-I) results in growth failure. A variety of molecular defects have been found to underlie severe primary IGF-I deficiency (IGFD), in which serum IGF-I concentrations are substantially decreased and fail to respond to GH therapy. Identification of more patients with primary or secondary IGFD is likely with investigative and diagnostic progress, particularly in the assessment of children with idiopathic short stature. Diagnosis of IGFD requires accurate and reliable IGF-I assays, adequate normative data for reference, and knowledge of IGF-I physiology for proper interpretation of data. Recombinant human IGF-I (rhIGF-I) treatment improves stature in patients with severe primary IGFD, and has also been shown to improve glycaemic control and insulin sensitivity in patients with severe insulin resistance. Ongoing studies of patients receiving rhIGF-I will allow further evaluation of the clinical utility of this treatment, with concurrent increase in our understanding of IGF-I and conditions of IGFD.
AB - Deficiency of insulin-like growth factor-I (IGF-I) results in growth failure. A variety of molecular defects have been found to underlie severe primary IGF-I deficiency (IGFD), in which serum IGF-I concentrations are substantially decreased and fail to respond to GH therapy. Identification of more patients with primary or secondary IGFD is likely with investigative and diagnostic progress, particularly in the assessment of children with idiopathic short stature. Diagnosis of IGFD requires accurate and reliable IGF-I assays, adequate normative data for reference, and knowledge of IGF-I physiology for proper interpretation of data. Recombinant human IGF-I (rhIGF-I) treatment improves stature in patients with severe primary IGFD, and has also been shown to improve glycaemic control and insulin sensitivity in patients with severe insulin resistance. Ongoing studies of patients receiving rhIGF-I will allow further evaluation of the clinical utility of this treatment, with concurrent increase in our understanding of IGF-I and conditions of IGFD.
U2 - 10.1515/JPEM.2010.23.1-2.3
DO - 10.1515/JPEM.2010.23.1-2.3
M3 - Journal article
VL - 23
SP - 3
EP - 16
JO - Journal of Pediatric Endocrinology and Metabolism
JF - Journal of Pediatric Endocrinology and Metabolism
SN - 0334-018X
IS - 1-2
ER -
ID: 34047679